Session 25: The Future of Natural Products in Drug Discovery
Thursday, July 24, 2014: 8:30 AM-11:30 AM
Regency Ballroom C, Second Floor (St. Louis Hyatt Regency at the Arch)
Convener:
Sheo Singh - SBS Pharma Consulting LLC, Edison, NJ
Natural products have been the source for well over 50% of drugs and drug leads. For some therapies, they serve as the exclusive source of drugs and drug leads. Despite historical success, there has been a downward trend in natural products research in the recent past. Gratifyingly newer technologies and approaches are leading a resurgence in natural products. This session will cover some of these approaches with an eye towards the future of natural products in drug discovery.

8:30 AM
S126
Role and future of natural products in drug discovery
Sheo B. Singh, President, Principal and Owner, SBS Pharma Consulting LLC, Edison, NJ
NP-SIM-St Louis-2014-Singh.pdf
9:00 AM
S127
Innovations in strain prioritization to streamline natural product discovery
Ben Shen, Departments of Chemistry and Molecular Therapeutics, and The Natural Products Library Initiative at TSRI, The Scripps Research Institute, Jupiter, FL
10:00 AM
S128
Aureolic acid anticancer drugs - history and future
Jürgen Rohr, Oleg Tsodikov, Markos Leggas, Jhong-min Chen, Xia Yu, Caixia Hou, Stevi Weidenbach and Jamie Horn, College of Pharmacy, University of Kentucky, Lexington, KY
10:30 AM
S129
Addressing natural product supply: Gram scale production of spliceostatins by Burkholderia sp
Alessandra S. Eustáquio, World-Wide Medicinal Chemistry, Pfizer Inc., Groton, CT
See more of: Invited Oral Papers
<< Previous Session | Next Session >>